Affymetrix Discloses 10 Percent Stake Held by Mazama | GenomeWeb
NEW YORK (GenomeWeb News) – Mazama Capital Management owns a 10 percent stake in Affymetrix’s Class A common stock, according to a filing with the US Securities and Exchange Commission today.
 
The Portland, Oregon-based investment advisory firm owned 6,783,041 shares of Affy’s common stock as of April 15.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.